Last reviewed 2026-04-20 · How we verify

2,2-Diethyl-1,3-Propanediol (prenderol)

2,2-Diethyl-1,3-Propanediol (generic name: prenderol) is a prenderol drug. It is currently in unknown development for Childhood absence epilepsy.

Prenderol works by modulating the activity of certain neurotransmitters in the brain to reduce seizure frequency.

2,2-Diethyl-1,3-Propanediol, also known as prenderol, is a small molecule drug in the prenderol class. It is used to treat childhood absence epilepsy, a condition characterized by brief, frequent seizures. The commercial status of prenderol is currently unknown, and it is not clear if it is patented or available as a generic medication. Further information on its pharmacokinetics, safety, and efficacy is needed. As a pharma professional, it is essential to consult the latest clinical data and regulatory information for accurate details.

At a glance

Mechanism of action

Imagine your brain is a busy city with many different streets and intersections. In people with childhood absence epilepsy, the streets get congested, and seizures occur. Prenderol helps to calm down the traffic by adjusting the flow of certain chemical messengers, or neurotransmitters, which helps to reduce the frequency of seizures.

Approved indications

• Childhood absence epilepsy

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• 2,2-Diethyl-1,3-Propanediol CI brief — competitive landscape report
• 2,2-Diethyl-1,3-Propanediol updates RSS · CI watch RSS
• portfolio CI

Frequently asked questions about 2,2-Diethyl-1,3-Propanediol

Related

• Drug class: All prenderol drugs
• Manufacturer: — full pipeline
• Therapeutic area: All drugs in Neuroscience
• Indication: Drugs for Childhood absence epilepsy

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing